Korro Bio, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $6.4M | $2.3M | $0 | $0 | $14.1M | $37.0M | $28.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $65.6M | $63.6M | $57.3M | $42.2M | $60.9M | $37.4M | $18.8M |
| SG&A Expense | — | $28.2M | $30.5M | $27.3M | $16.8M | $37.2M | $27.1M | $14.8M |
| Operating Income | — | $-121.9M | $-91.9M | $-84.5M | $-59.0M | $-84.0M | $-27.6M | $-20.7M |
| Operating Margin | — | -1,906.4% | -4,047.1% | — | — | -597.3% | -74.5% | -71.4% |
| Interest Expense | — | — | — | — | $961.0K | $764.0K | $0 | — |
| Pretax Income | — | $-116.6M | $-83.4M | $-81.1M | $-58.0M | $-84.7M | $-26.5M | $-18.7M |
| Income Tax Expense | — | $637.0K | $141.0K | $27.0K | $10.0K | $15.0K | $35.0K | $0 |
| Net Income | — | $-117.3M | $-83.6M | $-81.2M | $-58.0M | $-84.7M | $-26.5M | $-18.7M |
| Net Margin | — | -1,834.5% | -3,680.4% | — | — | -602.0% | -71.7% | -64.8% |
| EPS (Basic) | — | $-12.48 | $-9.37 | $-8.85 | $-6.32 | $-0.07 | $-0.02 | $-0.06 |
| EPS (Diluted) | — | $-12.48 | $-9.37 | $-8.85 | $-6.32 | $-0.07 | $-0.02 | $-0.06 |
| Shares Outstanding (Basic) | 14.4M | 9.4M | 8.9M | 9.2M | 9.2M | 1.25B | 1.22B | 1.11B |
| Shares Outstanding (Diluted) | 14.4M | 9.4M | 8.9M | 9.2M | 9.2M | 1.25B | 1.22B | 1.11B |
| Dividends Per Share | — | — | — | — | — | — | — | — |